Patients with Extensive-Stage SCLC May Benefit From Higher I-DXd Dose
Patients with extensive-stage small cell lung cancer (ES-SCLC) who were heavily pretreated saw benefits from treatments with ifinatamab deruxtecan (I-DXd), trial findings have shown. This improved efficacy was specifically apparent with a 12 milligram per …